Evidence map›Paper›PMID 19521507›Full record

ArticlePLoS pathogens2009

MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and Mycobacterium tuberculosis.

Dawn M E Bowdish, Kaori Sakamoto, Mi-Jeong Kim, Mariliis Kroos, Subhankar Mukhopadhyay, Cynthia A Leifer, Karl Tryggvason, Siamon Gordon, David G Russell

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 168 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
168citing papers in PubMed, 1 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

168 citing papers in PubMed, 1 synthesis or guideline pooled it, 307 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. HowVaccines · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Protein-Mediated Virulence in Mycobacterium tuberculosis.Advances in experimental medicine and biology · 2026
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Journal of medical microbiology · 2025
    Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

108 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Dawn M E BowdishSir William Dunn School of Pathology, University of Oxford, Oxford, UK.
Kaori Sakamoto
Mi-Jeong Kim
Mariliis Kroos
Subhankar Mukhopadhyay
Cynthia A Leifer
Karl Tryggvason
Siamon Gordon
David G Russell
University of Oxford · GBCornell University · USKarolinska Institutet · SEUniversity of Georgia · US

Funding

THE ROLE OF THE GRANULOMA IN M. TUBERCULOSIS INFECTIONSR01HL055936 · NHLBI · WASHINGTON UNIVERSITY · PI RUSSELL, DAVID G · 1995 to 2015
$5.4M
Development of a Novel Strategy of Adjuvant DiscoveryR01AI064430 · NIAID · CORNELL UNIVERSITY ITHACA · PI RUSSELL, DAVID G · 2005 to 2009
$2.0M
Toll-like receptor 9: trafficking and signalingR01AI076588 · NIAID · CORNELL UNIVERSITY · PI LEIFER, CYNTHIA A · 2009 to 2013
$1.8M
Medical Research CouncilNHLBI NIH HHS HL55936NHLBI NIH HHS R01 HL055936NIAID NIH HHS AI064430NIAID NIH HHS R01 AI064430NIAID NIH HHS R01 AI076588Wellcome Trust
6 · The paper itself

Abstract

Virtually all of the elements of Mycobacterium tuberculosis (Mtb) pathogenesis, including pro-inflammatory cytokine production, granuloma formation, cachexia, and mortality, can be induced by its predominant cell wall glycolipid, trehalose 6,6'-dimycolate (TDM/cord factor). TDM mediates these potent inflammatory responses via interactions with macrophages both in vitro and in vivo in a myeloid differentiation factor 88 (MyD88)-dependent manner via phosphorylation of the mitogen activated protein kinases (MAPKs), implying involvement of toll-like receptors (TLRs). However, specific TLRs or binding receptors for TDM have yet to be identified. Herein, we demonstrate that the macrophage receptor with collagenous structure (MARCO), a class A scavenger receptor, is utilized preferentially to "tether" TDM to the macrophage and to activate the TLR2 signaling pathway. TDM-induced signaling, as measured by a nuclear factor-kappa B (NF-kappaB)-luciferase reporter assay, required MARCO in addition to TLR2 and CD14. MARCO was used preferentially over the highly homologous scavenger receptor class A (SRA), which required TLR2 and TLR4, as well as their respective accessory molecules, in order for a slight increase in NF-kappaB signaling to occur. Consistent with these observations, macrophages from MARCO(-/-) or MARCO(-/-)SRA(-/-) mice are defective in activation of extracellular signal-related kinase 1/2 (ERK1/2) and subsequent pro-inflammatory cytokine production in response to TDM. These results show that MARCO-expressing macrophages secrete pro-inflammatory cytokines in response to TDM by cooperation between MARCO and TLR2/CD14, whereas other macrophage subtypes (e.g. bone marrow-derived) may rely somewhat less effectively on SRA, TLR2/CD14, and TLR4/MD2. Macrophages from MARCO(-/-) mice also produce markedly lower levels of pro-inflammatory cytokines in response to infection with virulent Mtb. These observations identify the scavenger receptors as essential binding receptors for TDM, explain the differential response to TDM of various macrophage populations, which differ in their expression of the scavenger receptors, and identify MARCO as a novel component required for TLR signaling.

Indexed as

AnimalsCHO CellsCord FactorsCricetinaeCricetulusCytokinesCytoplasmHumansLipopolysaccharide ReceptorsMacrophagesMiceMice, Inbred C57BLMicroscopy, FluorescenceMicrospheresMycobacterium tuberculosisPhagosomesCord FactorsCytokinesLipopolysaccharide ReceptorsMARCO protein, humanMarco protein, mouseReceptors, ImmunologicScavenger Receptors, Class ATLR2 protein, humanTLR4 protein, humanToll-Like Receptor 2Toll-Like Receptor 4

Identifiers

PMID19521507
PMCPMC2688075
OpenAlexW1985779248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.